John Michael Ellis

This inventor holds 19 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 17 EPO patents, primarily in Spleen Tyrosine Kinase Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc., Celgene Corporation. Active years: 2012-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Michael Ellis. Retrieved from https://idiyas.com/inventor/john-michael-ellis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 4)

% Patents Active = 89.5

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 17 (Patent Applications = 21)

Average Co-Inventor Count = 6.9

ph-index = 8

Forward Citations = 117(Granted Patents)

Location History:

Mansfield, OH (US) (2012)
Needham, MA (US) (2013 - 2021)

Company Filing History:

17 out of 2,405

Merck Sharp + Dohme Corp.

4. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

Areas of Expertise:

Thienopyridine

Thiazole

Aminoheteroaryls

Spleen Tyrosine Kinase

Triazolyl Derivatives

Imidazolyl Analogs

Pyridine

Phenyl Carboxamide

Aminopyrimidines

Pyrazolyl Derivatives

Bipyridylaminopyridines

Carboxamides

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11168093 - Thienopyridine inhibitors of RIPK2 (2021-11-09),

2. 9822107 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-11-21),

3. 9775839 - 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors (2017-10-03),

4. 9745295 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-08-29),

5. 9598405 - Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors (2017-03-21),

6. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

7. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),

8. 9416111 - Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors (2016-08-16),

9. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),

10. 9353066 - Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors (2016-05-31),

11. 9290490 - Aminopyrimidines as Syk inhibitors (2016-03-22),

12. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),

13. 9216173 - 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors (2015-12-22),

14. 9145391 - Bipyridylaminopyridines as Syk inhibitors (2015-09-29),

15. 9120785 - Pyridyl aminopyridines as Syk inhibitors (2015-09-01),

Title: Innovations and Contributions of John Michael Ellis in the Pharmaceutical Field

Introduction: John Michael Ellis, an accomplished inventor based in Needham, MA, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 19 patents. His work primarily focuses on developing innovative compounds that target specific biological pathways, advancing the treatment of various diseases.

Latest Patents: Among Ellis's notable patents are his recent innovations:

- **Thienopyridine Inhibitors of RIPK2**: This invention presents novel compounds, along with pharmaceutically acceptable compositions, and outlines methods for their use in medical applications.

- **Thiazole-Substituted Aminoheteroaryls as Spleen Tyrosine Kinase Inhibitors**: This patent introduces specific thiazole-substituted aminoheteroaryl compounds and their pharmaceutically acceptable salts. It also provides pharmaceutical compositions comprising these compounds, designed to treat conditions mediated by Spleen Tyrosine Kinase (Syk).

Career Highlights: John Michael Ellis has an established career in the pharmaceutical industry, having worked with prestigious companies such as Merck Sharp & Dohme Corporation and Merck Canada Inc. His expertise in drug design and development has significantly influenced the advancement of new therapeutic solutions.

Collaborations: Throughout his career, Ellis has collaborated with notable coworkers, including Alan B Northrup and Michael D Altman. These collaborations have fostered an environment of innovation and creativity, leading to impactful developments in pharmaceutical research.

Conclusion: John Michael Ellis exemplifies the spirit of innovation in the pharmaceutical sector. With his extensive patent portfolio and collaborations with industry leaders, his contributions continue to influence medical science and improve patient outcomes. His work highlights the essential role inventors play in driving advancements in healthcare.

Profile summary based on public USPTO records.